newsfilter
← Latest News
GlobeNewswire·

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

YDES
  • YD Bio Limited (NASDAQGM: YDES) announced support for the global commercialization of OkaiDx™, a research-use-only blood test for post-treatment breast cancer monitoring.
  • OkaiDx™ is now available through EG Biomed US Inc.'s CLIA/CAP-certified laboratory in the United States via an affiliate arrangement.
  • The assay utilizes cfDNA methylation profiling to generate molecular surveillance data for research settings, academic groups, & industry partners.
  • Dr. Ethan Shen, CEO of YD Bio, cited independent validation metrics showing 95.1% accuracy, 89.4% sensitivity, & 96.5% specificity.
  • The test is intended strictly for research use & has not received clearance or approval from the U.S. Food and Drug Administration.
  • YD Bio will assist with commercialization efforts, researcher engagement, & sample logistics to complement EG BioMed's laboratory capabilities.
  • OkaiDx™ performance data has been published in peer-reviewed journals such as Clinical Epigenetics & Biomolecules & presented at major oncology conferences.
  • YD Bio Limited is a biotechnology firm focused on DNA methylation cancer detection, ophthalmologic innovations, & clinical trial drug supply.
  • The announcement includes standard forward-looking statements warning of risks & uncertainties regarding future business expectations.